FDA Approves the First Heart Valve Designed to Expand as a Child Grows

On October 1, 2026, the U.S. Food and Drug Administration approved the Autus Size-Adjustable Valve, the first U.S.-approved heart valve designed to be expanded after implantation to accommodate a child's growth.

The device is a surgically implanted pulmonary valve for selected pediatric patients with congenital pulmonary valve disease who require pulmonary valve replacement. It is not intended for every congenital heart condition and does not replace all forms of pediatric cardiac surgery.

Conventional prosthetic heart valves have a fixed size. As a child grows, a valve implanted at a young age can become relatively too small, restricting blood flow or creating another functional problem.

Traditional valve leaflets are also often made from animal tissue, which can calcify or deteriorate more quickly in children. Pediatric teams must therefore balance the burden of disease, the timing of intervention and the likelihood of multiple open-heart operations over a child's lifetime.

The Autus valve can be implanted with an internal diameter of approximately 13 millimeters and later expanded with a balloon catheter delivered through a blood vessel. It can ultimately reach approximately 22 millimeters, a size comparable to an adult pulmonary valve. The goal is to adjust the valve when a child outgrows its initial diameter without performing open-heart surgery solely to place a larger valve.

Its leaflets are made from a synthetic polymer rather than animal tissue. According to the FDA, this is the first approved heart valve in the United States to use polymeric leaflets. Whether the material will maintain performance over many years in children still requires long-term observation.

FDA approval information indicates that the device is for pediatric patients weighing at least 10 kilograms who have been determined to need surgical pulmonary valve replacement. They must have a dysfunctional native or surgically repaired right ventricular outflow tract and meet defined echocardiographic criteria for pulmonary stenosis, pulmonary regurgitation or both.

Eligibility depends on echocardiography, previous operations, right ventricular function, body size and other health considerations. A pediatric cardiology and cardiac surgery team must evaluate the individual patient. The phrase 'a valve that grows' cannot replace assessment of the approved indication and surgical risks.

The approval was supported by a prospective, single-arm, multicenter study. An early feasibility cohort and the pivotal study together included 62 children treated across 12 U.S. medical centers.

All patients underwent successful implantation. At six months, the first 60 patients met the prespecified hemodynamic performance criteria, with no more than mild pulmonary regurgitation. The study reported no deaths, strokes or blood clots requiring treatment.

Three patients experienced a valve-frame fracture, and two had reduced movement of one leaflet. FDA information states that these events did not cause symptoms at the time, but they remain device-related findings that require continued follow-up.

Two children whose valve performance began to decline as they grew underwent successful balloon expansion without another open-heart operation. These cases support the basic feasibility of the design.

Two patients, however, cannot answer all questions about expansion at different ages, in different anatomies or after repeated procedures. The FDA specifically notes that post-implant expansion experience is limited. Early results should not be interpreted to mean that every child will avoid future surgery.

The pivotal study plans annual follow-up for up to ten years after implantation. Researchers will assess valve function, stenosis and regurgitation, frame integrity, thrombosis, infection, reintervention, quality of life and performance after expansion.

The FDA also requires post-approval studies and further testing of frame durability. For a high-risk device intended to remain in the body for years, approval means that current evidence supports a favorable benefit-risk balance for its intended use. It does not mean every long-term uncertainty has been resolved.

This approval reflects a shift in pediatric device development from adapting smaller versions of adult products toward designing technologies around childhood growth and lifelong needs. If long-term studies confirm safe expansion and durable valve function, the device could reduce repeat open-heart operations for selected children.

For now, 'may reduce' is more accurate than 'will eliminate' additional surgery. Long-term durability, repeated expansion and real-world outcomes remain under evaluation. Families should discuss eligibility, alternatives, lifelong surveillance and the possibility of future intervention with a team experienced in congenital heart disease.

This article summarizes public FDA, ClinicalTrials.gov and professional information about an international medical and regulatory development. It does not recommend a medical device or provide diagnosis or individualized treatment advice. Decisions should be made by appropriately qualified pediatric cardiac professionals.